Julie Brahmer, KEYNOTE-024: Pembrolizumab double the 5-year OS rate for patients with metastatic, PD-L1-positive lung cancer vs chemotherapy.

Johann de Bono presented the first results from the phase III study IPATential150 at this year’s ESMO Virtual Congress 2020. In IPATential150 ipatasertib is given in combination with abiraterone to patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) who had not previously been treated for mCRPC. 40-50% of mCRPC patients have loss of PTEN, which leads to overactivation of the PI3K/AKT signaling pathway. Patients have a poor prognosis and it is also associated with an inferior effect of androgen receptor blockade. Co-primary endpoints are radiologically progression-free survival (rPFS) with the group with PTEN loss detected histologically and for the ITT group. The study showed a significant improvement of two months progression-free survival in the group with loss of PTEN, but not in the ITT population. It is too early to assess the overall survival in the study as data are not mature. In the iparsertib and abiraterone…

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

Positive results with immunotherapy in combination with the chemotherapy nab paclitaxel in 1st line treatment of triple-negative and PD-L1-positive metastatic breast cancer. Disappointing results with the combination with paclitaxel suggest that the choice of chemotherapy is of great importance. Updated results from the phase III study IMpassion130, where atezolizumab was given in combination with nab-paclitaxel, and new data from IMpassion131, where chemotherapy was changed to paclitaxel, were presented at this year’s virtual ESMO Congress 2020. As early as January, the Danish Medicines Agency recommended that patients with triple-negative breast cancer should be treated with atezolizumab in combination with nab paclitaxel on the basis of positive results in the IMpassion130 study. Quite unexpectedly, IMpassion131 showed no effect of adding atezolizumab to paclitaxel. With the same study design and comparable patient population in the studies, a number of questions arise. Is it due to the choice of chemotherapy and thus differences in…

In this MEDtalk Ken Kato, MD. PhD, National Cancer Center Hospital, Tokyo, presents the results of the KEYNOTE 590 study.

A planned interim analysis of the phase III study CROWN shows a significant improvement in progression-free survival (PFS) and a reduction in the incidence of brain metastases for lorlatinib compared to crizotinib in 1L treatment of patients with ALK positive stage IIIB/IV non-small cell lung cancer (NSCLC). The analysis was presented by Professor Benjamin Solomon from Melbourne at the Presidential Symposium at ESMO 2020. After 12 months of treatment, the PFS rate was 78% in the lorlatinib arm compared to 39% in the crizotinib arm (HR = 0.28 95% CI 0.19-0.41, P <0.001). Intracranial objective response rate was 66% in the lorlatinib arm and 20% in the crizotinib arm. There were more grade 3/4 adverse reactions with lorlatinib (72.5%) compared to crizotinib (55.6%), and fewer patients completed the treatment compared with crizotinib (6.7% versus 9.2%). For more information: LBA2 - Lorlatinib vs crizotinib in the first-line treatment of patients (pts)…

#Tuorein julkaisu

Onkologia/ hematologia 3/2020

Nro. 3 elokuu 2020
  • ASCO 2020
  • Melanooma
  • Syöpäpotilaan kohtaaminen

ASCO20 Virtual

Special Issue

Updates on COVID-19



Levinneen kastraatioresistentin eturauhassyövän sädehoito

Asiantuntija: Petteri Hervonen

Kesto: 1:41

Levinneen kastraatioresistentin eturauhassyövän hoidon seuranta

Asiantuntija: Petteri Hervonen

Kesto: 2:17

Kastraatioresistentin eturauhassyövän diagnostiikka

Asiantuntija: Antti Rannikko

Kesto: 5:07

EHA 2019

ASCO 2019


Onkologia ja Hematologia

Heikki Minn

Heikki Minn

Taina Turpeenniemi-Hujanen

Taina Turpeenniemi-Hujanen
professori, ylilääkäri

Vesa Kataja

Vesa Kataja
dosentti, johtajaylilääkäri